Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

July 2022 | 63 pages | ID: M67A58917CFBEN
Global Markets Direct

Abstracts

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Melanocyte-stimulating hormone receptor (MSHR) also known as melanocortin 1 receptor (MC1R), is a G protein-coupled receptor that binds to a peptide hormones known as the melanocortins, which include adrenocorticotropic hormone (ACTH). When activated by alpha-MSH, MC1R initiates a complex signaling cascade that leads to the production of the brown or black pigment eumelanin. The receptor also antagonize by agouti signaling peptide which reverts the cell back to producing the yellow or red phaeomelanin.

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) pipeline Target constitutes close to 12 molecules. Out of which approximately 12 molecules are developed by Companies.The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 4, 1, 1 and 6 respectively. Report covers products from therapy areas Metabolic Disorders, Dermatology, Gastrointestinal, Genito Urinary System And Sex Hormones, Immunology, Ophthalmology, Genetic Disorders, Infectious Disease, Cardiovascular, Central Nervous System, Musculoskeletal Disorders, Oncology and Respiratory which include indications Diabetic Retinopathy, Inflammatory Bowel Disease, Porphyria (Erythropoietic Protoporphyri), Uveitis, Vitiligo, Acne Vulgaris, Acute Ischemic Stroke, Choroidal Neovascularization, Coronavirus Disease 2019 (COVID-19), Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome, IgA Nephropathy (Berger's Disease), Inflammation, Keratoconjunctivitis Sicca (Dry Eye), Kidney Disease (Nephropathy), Metastatic Melanoma, Multiple Sclerosis, Nephrotic Syndrome, Peritonitis, Porphyria Variegata, Psoriatic Arthritis, Pulmonary Fibrosis, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Systemic Sclerosis (Scleroderma), Ulcerative Colitis and Unspecified Dermatological Disorders.

The latest report Melanocyte Stimulating Hormone Receptor - Drugs In Development, 2022, outlays comprehensive information on the Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R)
• The report reviews Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics and enlists all their major and minor projects
• The report assesses Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and @Scope

Contents

Introduction
Global Markets Direct Report Coverage
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Overview
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Companies Involved in Therapeutics Development
Clinuvel Pharmaceuticals Ltd
Mallinckrodt Plc
Mitsubishi Tanabe Pharma Corp
Palatin Technologies Inc
SynAct Pharma AB
Viewpoint Molecular Targeting LLC
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Drug Profiles
afamelanotide acetate - Drug Profile
Product Description
Mechanism Of Action
History of Events
AP-1189 - Drug Profile
Product Description
Mechanism Of Action
History of Events
corticotropin - Drug Profile
Product Description
Mechanism Of Action
History of Events
CUV-9900 - Drug Profile
Product Description
Mechanism Of Action
History of Events
dersimelagon phosphate - Drug Profile
Product Description
Mechanism Of Action
History of Events
Next Generation of Compounds - Drug Profile
Product Description
Mechanism Of Action
Parvysmelanotide - Drug Profile
Product Description
Mechanism Of Action
History of Events
PL-8177 - Drug Profile
Product Description
Mechanism Of Action
History of Events
PL-8331 - Drug Profile
Product Description
Mechanism Of Action
History of Events
PL-9643 - Drug Profile
Product Description
Mechanism Of Action
History of Events
PL-9654 - Drug Profile
Product Description
Mechanism Of Action
History of Events
VMT-01 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Dormant Products
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Discontinued Products
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Product Development Milestones
Featured News & Press Releases
Jun 29, 2022: SynAct Pharma recieves pre-IND response from the US FDA
Jun 22, 2022: SynAct Pharma submits CTA for clinical phase 2b study in RA
May 17, 2022: New retrospective data on African Americans with advanced symptomatic sarcoidosis treated with Acthar Gel (repository corticotropin injection) presented at the American Thoracic Society Annual International Conference
May 10, 2022: Clinuvel progresses vitiligo study
May 09, 2022: CLINUVEL progresses vitiligo treatment program
May 04, 2022: CLINUVEL Pharmaceuticals : Positive final results in stroke
May 04, 2022: SynAct Pharma completes clinical pharmacokinetic test of AP1189 tablet
May 02, 2022: Palatin to present on PL9643 at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Conference
May 02, 2022: Palatin to present on PL-9654 at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Conference
May 02, 2022: Palatin to present on PL8177 at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Conference
Apr 21, 2022: Palatin to present at Eyecelerator American Society of Cataract and Refractive Surgery (ASCRS) 2022
Mar 15, 2022: Afamelanotide in stroke (AIS) - Positive preliminary results
Mar 03, 2022: Palatin hosting key opinion leader webinar on dry eye disease
Feb 14, 2022: CLINUVEL expands DNA repair program with 2nd DNA repair study
Jan 22, 2022: SCENESSE continued in Germany
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Clinuvel Pharmaceuticals Ltd, 2022
Pipeline by Mallinckrodt Plc, 2022
Pipeline by Mitsubishi Tanabe Pharma Corp, 2022
Pipeline by Palatin Technologies Inc, 2022
Pipeline by SynAct Pharma AB, 2022
Pipeline by Viewpoint Molecular Targeting LLC, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022